Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
CCEL 
CryoCell International Inc (CCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: CCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit 14.97% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 50.51M USD | Price to earnings Ratio 125 | 1Y Target Price 8.5 |
Price to earnings Ratio 125 | 1Y Target Price 8.5 | ||
Volume (30-day avg) 15722 | Beta 0.64 | 52 Weeks Range 5.41 - 8.93 | Updated Date 04/2/2025 |
52 Weeks Range 5.41 - 8.93 | Updated Date 04/2/2025 | ||
Dividends yield (FY) 15.53% | Basic EPS (TTM) 0.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 1.26% | Operating Margin (TTM) -1.54% |
Management Effectiveness
Return on Assets (TTM) 3.76% | Return on Equity (TTM) 129.2% |
Valuation
Trailing PE 125 | Forward PE - | Enterprise Value 61486880 | Price to Sales(TTM) 1.58 |
Enterprise Value 61486880 | Price to Sales(TTM) 1.58 | ||
Enterprise Value to Revenue 1.92 | Enterprise Value to EBITDA 10.81 | Shares Outstanding 8082160 | Shares Floating 4425790 |
Shares Outstanding 8082160 | Shares Floating 4425790 | ||
Percent Insiders 40.17 | Percent Institutions 12.76 |
Analyst Ratings
Rating 4 | Target Price 9 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
CryoCell International Inc
Company Overview
History and Background
Cryo-Cell International, Inc. was founded in 1989 and is one of the first private cord blood banks. They focus on the cryopreservation of umbilical cord blood and cord tissue for potential future use. The company has evolved to offer other services such as genetic testing and newborn screening.
Core Business Areas
- Cord Blood Banking: Collection, processing, and storage of umbilical cord blood stem cells.
- Cord Tissue Banking: Collection, processing, and storage of umbilical cord tissue.
- Newborn Screening: Offerings of genetic testing and screening services for newborns.
- Family Health DNA Testing: Provides genetic testing for families. Tests for genetic predispositions for certain conditions
Leadership and Structure
Detailed information on the leadership team and organizational structure is not readily available without deeper research. Typically, it would include a CEO, CFO, and other key executives, along with a board of directors.
Top Products and Market Share
Key Offerings
- Cord Blood Banking: Cryo-Cell's primary offering is cord blood storage. Market share data is difficult to ascertain precisely. Competitors include Cord Blood Registry (CBR), ViaCord, and Americord Registry. The Cord Blood banking market is expected to reach $44.75 billion by 2031.
- Cord Tissue Banking: Cryopreservation of cord tissue is another core service. Market share data is not easily obtained. Competitors include Cord Blood Registry (CBR), ViaCord, and Americord Registry.
- Newborn Screening: Screening for metabolic and genetic disorders soon after birth. Competition includes PerkinElmer and Natera.
Market Dynamics
Industry Overview
The cord blood banking industry is driven by growing awareness of the therapeutic potential of stem cells and genetic testing/screening is growing due to greater patient awareness. However, it is also impacted by debates on the necessity of private vs. public banking.
Positioning
Cryo-Cell is positioned as an established player in the private cord blood banking market. Their competitive advantage lies in their long history, brand recognition, and comprehensive service offerings.
Total Addressable Market (TAM)
The global cord blood banking market is expected to reach billions of dollars. Cryo-Cell's TAM is limited to a portion of that total market as the company is a private entity. Cryo-Cell focuses on customers willing to pay for their private cord blood banking services.
Upturn SWOT Analysis
Strengths
- Established brand recognition
- Long history in the industry
- Comprehensive service offerings (cord blood, cord tissue, genetic testing)
- Strong focus on customer service
Weaknesses
- Relatively higher price point compared to some competitors
- Dependence on consumer awareness and marketing efforts
- Limited diversification beyond core services
Opportunities
- Expanding into new geographic markets
- Developing new stem cell-based therapies
- Partnering with hospitals and clinics
- Capitalizing on the increasing demand for family genetic testing
Threats
- Competition from larger, well-funded companies
- Public debate on the necessity of private cord blood banking
- Changes in regulatory requirements
- Economic downturn impacting consumer spending
- Evolving stem cell research shifting focus away from cord blood
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Viacord
- CBR Systems Inc.
Competitive Landscape
Cryo-Cell faces competition from larger, well-funded companies with broader service offerings. Their advantage lies in their established brand and specialized focus. To remain competitive, they need to continue innovating and expanding their service offerings.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on marketing efforts, new client acquisition, and customer retention. Access to financial reports is needed to provide accurate growth trends.
Future Projections: Without access to analyst reports, future growth projections cannot be accurately provided.
Recent Initiatives: Initiatives include expanding genetic testing services and partnerships with healthcare providers. Specific details require company announcements or press releases.
Summary
Cryo-Cell International is an established player in the cord blood banking market with a long history and a strong brand. However, competition is fierce, and the company faces challenges from larger competitors and changing market dynamics. Their focus on customer service and specialized services are important strengths. Future success relies on innovation, geographic expansion, and strategic partnerships.
Similar Companies
TMO
Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Market Research Reports
- SEC Filings (where available)
Disclaimers:
The data provided is based on publicly available information and may not be entirely accurate or up-to-date. This is not financial advice, and any investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About CryoCell International Inc
Exchange NYSE MKT | Headquaters Oldsmar, FL, United States | ||
IPO Launch date 1997-01-21 | Chairman & Co-CEO Mr. David I. Portnoy | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 82 | Website https://www.cryo-cell.com |
Full time employees 82 | Website https://www.cryo-cell.com | ||
Cryo-Cell International, Inc. engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells, which are used in regenerative medicine to treat a range of conditions. The company manufactures and sells PrepaCyte CB processing system, a technology used to process umbilical cord blood stem cells. It markets its cord blood stem cell preservation services directly to expectant parents, as well as by distributing information through obstetricians, pediatricians, childbirth educators, certified nurse-midwives, and other related healthcare professionals. The company was incorporated in 1989 and is headquartered in Oldsmar, Florida.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.